Skip to main content
SpringerLink
Log in

Haematological cancer

Cytarabine — new standard of care for MCL

  • Research Highlight
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hermine, O. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet http://dx.doi.org/10.1016/S0140-6736(16)00739-X (2016)

Download references

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Cytarabine — new standard of care for MCL. Nat Rev Clin Oncol 13, 464–465 (2016). https://doi.org/10.1038/nrclinonc.2016.104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.104

  • Springer Nature Limited

Search

Navigation